{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:37:35Z","timestamp":1790195855978,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0804500\/2020YFA0804501"],"award-info":[{"award-number":["2020YFA0804500\/2020YFA0804501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clinbiochem.2022.11.013","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T12:44:48Z","timestamp":1670244288000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["How far is the goal of applying \u03b2-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer\u2019s disease with standardization of measurements?"],"prefix":"10.1016","volume":"112","author":[{"given":"Yutong","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0010","doi-asserted-by":"crossref","unstructured":"L. Jia, Y. Du, L. Chu, Z. Zhang, F. Li, D. Lyu, Y. Li, Y. Li, M. Zhu, H. Jiao, Y. Song, Y. Shi, H. Zhang, M. Gong, C. Wei, Y. Tang, B. Fang, D. Guo, F. Wang, A. Zhou, C. Chu, X. Zuo, Y. Yu, Q. Yuan, W. Wang, F. Li, S. Shi, H. Yang, C. Zhou, Z. Liao, Y. Lv, Y. Li, M. Kan, H. Zhao, S. Wang, S. Yang, H. Li, Z. Liu, Q. Wang, W. Qin, J. Jia, Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study, Lancet Public Health 5(12) (2020) e661-e671.","DOI":"10.1016\/S2468-2667(20)30185-7"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.013_b0025","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/humu.22117","article-title":"Locus-specific mutation databases for neurodegenerative brain diseases","volume":"33","author":"Cruts","year":"2012","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"12","key":"10.1016\/j.clinbiochem.2022.11.013_b0035","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","article-title":"Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment","volume":"74","author":"Janelidze","year":"2017","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-022-01003-w","article-title":"The cerebrospinal fluid biomarker ratio A\u03b242\/40 identifies amyloid positron emission tomography positivity better than A\u03b242 alone in a heterogeneous memory clinic cohort","volume":"14","author":"Amft","year":"2022","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease","volume":"11","author":"Blennow","year":"2015","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","article-title":"Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative","volume":"8","author":"Vanderstichele","year":"2012","journal-title":"Alzheimers Dement."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.013_b0055","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement."},{"issue":"11","key":"10.1016\/j.clinbiochem.2022.11.013_b0060","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/alz.12145","article-title":"First amyloid \u03b21-42 certified reference material for re-calibrating commercial immunoassays","volume":"16","author":"Boulo","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.11.013_b0065","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00259-021-05258-7","article-title":"2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0070","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/JAD-170327","article-title":"The Cerebrospinal Fluid A\u03b21-42\/A\u03b21-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting","volume":"60","author":"Niemantsverdriet","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"10","key":"10.1016\/j.clinbiochem.2022.11.013_b0075","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid \u03b2-amyloid 42: a cross-validation study against amyloid positron emission tomography","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.clinbiochem.2022.11.013_b0080","doi-asserted-by":"crossref","first-page":"e0221365","DOI":"10.1371\/journal.pone.0221365","article-title":"Amyloid-\u03b2 PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheime\u0155s disease diagnosis in a memory clinic","volume":"14","author":"M\u00fcller","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0085","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3233\/JAD-170582","article-title":"[18F]-flutemetamol uptake in cortex and white matter: comparison with cerebrospinal fluid biomarkers and [18F]-fludeoxyglucose","volume":"62","author":"Kalheim","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JAD-170753","article-title":"Clinic-based validation of cerebrospinal fluid biomarkers with florbetapir PET for diagnosis of dementia","volume":"61","author":"\u00c1lvarez","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13195-015-0159-5","article-title":"Diagnostic value of cerebrospinal fluid A\u03b2 ratios in preclinical Alzheimer's disease","volume":"7","author":"Adamczuk","year":"2015","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13195-019-0543-7","article-title":"Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes","volume":"11","author":"Carandini","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/WNL.0000000000002081","article-title":"Use of amyloid-PET to determine cutpoints for CSF markers: a multicenter study","volume":"86","author":"Zwan","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.11.013_b0110","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/gerona\/61.7.755","article-title":"Cerebrospinal fluid amyloid beta42\/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia","volume":"61","author":"de Jong","year":"2006","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JAD-130203","article-title":"The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study","volume":"36","author":"Molinuevo","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-141725","article-title":"Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort","volume":"44","author":"Seeburger","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.11.013_b0125","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1373\/clinchem.2006.081679","article-title":"Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins","volume":"53","author":"Reijn","year":"2007","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3233\/JAD-131085","article-title":"Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls","volume":"41","author":"Struyfs","year":"2014","journal-title":"J. Alzheimers Dis."},{"issue":"12","key":"10.1016\/j.clinbiochem.2022.11.013_b0135","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00702-002-0763-y","article-title":"CSF markers related to pathogenetic mechanisms in Alzheimer's disease","volume":"109","author":"Mulder","year":"2002","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"8","key":"10.1016\/j.clinbiochem.2022.11.013_b0140","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","article-title":"Improved discrimination of AD patients using beta-amyloid(1\u201342) and tau levels in CSF","volume":"52","author":"Hulstaert","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-160176","article-title":"Association between cerebrospinal fluid biomarkers for Alzheimer's disease, APOE genotypes and auditory verbal learning task in subjective cognitive decline, mild cognitive impairment, and Alzheimer's disease","volume":"54","author":"Mandecka","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3233\/JAD-2012-121246","article-title":"Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia","volume":"33","author":"Le Bastard","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2022.11.013_b0155","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jns.2015.09.022","article-title":"Cerebrospinal fluid A\u03b240 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease","volume":"358","author":"Baldeiras","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/13554790490896785","article-title":"Biomarker profiles and their relation to clinical variables in mild cognitive impairment","volume":"11","author":"Schoonenboom","year":"2005","journal-title":"Neurocase"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0165","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3233\/JAD-160494","article-title":"Cerebrospinal fluid biomarkers as a diagnostic tool of the underlying pathology of primary progressive aphasia","volume":"55","author":"Paraskevas","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.013_b0170","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.neurobiolaging.2005.06.005","article-title":"Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample","volume":"27","author":"Ibach","year":"2006","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0175","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1468-1331.2006.01593.x","article-title":"Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease","volume":"14","author":"Kapaki","year":"2007","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.11.013_b0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s007020070079","article-title":"CSF levels of tau, beta-amyloid(1\u201342) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging","volume":"107","author":"Sj\u00f6gren","year":"2000","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1468-1331.2003.00562.x","article-title":"CSF tau protein and beta-amyloid (1\u201342) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population","volume":"10","author":"Kapaki","year":"2003","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0190","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3233\/JAD-140405","article-title":"Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study","volume":"42","author":"Van der Mussele","year":"2014","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.11.013_b0195","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.0000000000001859","article-title":"Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease","volume":"85","author":"Alcolea","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/JAD-160298","article-title":"Performance evaluation of an automated ELISA system for Alzheimer's disease detection in clinical routine","volume":"54","author":"Chiasserini","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"8","key":"10.1016\/j.clinbiochem.2022.11.013_b0205","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/gps.1351","article-title":"The diagnostic value of tau protein, beta-amyloid (1\u201342) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages","volume":"20","author":"Kapaki","year":"2005","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"5\u20136","key":"10.1016\/j.clinbiochem.2022.11.013_b0210","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000091436","article-title":"The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease","volume":"21","author":"Brettschneider","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.11.013_b0215","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.56.6.673","article-title":"Cerebrospinal fluid beta-amyloid(1\u201342) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease","volume":"56","author":"Andreasen","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1034\/j.1600-0404.107.s179.9.x","article-title":"Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment","volume":"179","author":"Andreasen","year":"2003","journal-title":"Acta Neurol. Scand. Suppl."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0225","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-141986","article-title":"Diagnostic accuracy of cerebrospinal fluid amyloid-\u03b2 isoforms for early and differential dementia diagnosis","volume":"45","author":"Struyfs","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0230","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0235","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3233\/JAD-130107","article-title":"Cerebrospinal fluid A\u03b21-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels","volume":"36","author":"Slaets","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0240","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","article-title":"Amyloid-beta(1\u201342), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease","volume":"56","author":"Mulder","year":"2010","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0245","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3233\/JAD-151097","article-title":"A decade of cerebrospinal fluid biomarkers for Alzheimer's disease in Belgium","volume":"54","author":"Somers","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13195-016-0233-7","article-title":"Unbiased estimates of cerebrospinal fluid \u03b2-amyloid 1\u201342 cutoffs in a large memory clinic population","volume":"9","author":"Bertens","year":"2017","journal-title":"Alzheimers Res. Ther."},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.11.013_b0255","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0404.2011.01592.x","article-title":"Alzheimer CSF biomarkers in routine clinical setting","volume":"125","author":"Tabaraud","year":"2012","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.11.013_b0260","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00415-014-7335-6","article-title":"The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials","volume":"261","author":"Dumurgier","year":"2014","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.013_b0265","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1212\/01.WNL.0000123249.58898.E0","article-title":"Amyloid beta(1\u201342) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease","volume":"62","author":"Schoonenboom","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0270","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jalz.2012.06.006","article-title":"Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting","volume":"9","author":"Dumurgier","year":"2013","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0275","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jalz.2012.01.004","article-title":"Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study","volume":"9","author":"Jongbloed","year":"2013","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3233\/JAD-121549","article-title":"Impact of the 2008\u20132012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study","volume":"34","author":"Gabelle","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.013_b0285","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.biopsych.2011.11.031","article-title":"Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease","volume":"71","author":"Mouton-Liger","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0290","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-2011-111349","article-title":"Performance of a\u03b21-40, a\u03b21-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment","volume":"29","author":"Parnetti","year":"2012","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WAD.0000000000000126","article-title":"Performance of cerebrospinal fluid biomarkers of Alzheimer disease in a memory clinic in Norway","volume":"30","author":"Knapskog","year":"2016","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0300","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00702-008-0177-6","article-title":"Combined CSF tau, p-tau181 and amyloid-beta 38\/40\/42 for diagnosing Alzheimer's disease","volume":"116","author":"Welge","year":"2009","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0305","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JAD-2011-110515","article-title":"Decreased sA\u03b2PP\u03b2, A\u03b238, and A\u03b240 cerebrospinal fluid levels in frontotemporal dementia","volume":"26","author":"Gabelle","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0310","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3233\/JAD-160398","article-title":"Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-\u03b2 peptides in human cerebrospinal fluid and application to a clinical cohort","volume":"54","author":"Klafki","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.11.013_b0315","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/01.WNL.0000156914.16988.56","article-title":"CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment","volume":"64","author":"Herukka","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0320","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3233\/JAD-160360","article-title":"Combining cerebrospinal fluid biomarkers and neuropsychological assessment: a simple and cost-effective algorithm to predict the progression from mild cognitive impairment to Alzheimer's Disease dementia","volume":"54","author":"Mazzeo","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.11.013_b0325","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000100926","article-title":"Prediction of Alzheimer's disease using the CSF Abeta42\/Abeta40 ratio in patients with mild cognitive impairment","volume":"23","author":"Hansson","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0330","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000229023","article-title":"Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1\u201342) levels","volume":"28","author":"Papaliagkas","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neulet.2003.08.011","article-title":"Cerebrospinal fluid markers for prediction of Alzheimer's disease","volume":"352","author":"Zetterberg","year":"2003","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.013_b0340","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","article-title":"Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age","volume":"72","author":"Sutphen","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0345","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13195-020-00767-3","article-title":"Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans","volume":"13","author":"Moon","year":"2021","journal-title":"Alzheimers Res. Ther."},{"issue":"8","key":"10.1016\/j.clinbiochem.2022.11.013_b0350","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1533317513504615","article-title":"Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study","volume":"28","author":"Shea","year":"2013","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2022.11.013_b0355","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2005.05.015","article-title":"Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration","volume":"237","author":"Noguchi","year":"2005","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0360","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000320265","article-title":"A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic","volume":"30","author":"Morinaga","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0365","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JAD-170128","article-title":"Concordance between cerebrospinal fluid biomarkers with Alzheimer's disease pathology between three independent assay platforms","volume":"61","author":"Doecke","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0370","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s007020170091","article-title":"Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients","volume":"108","author":"R\u00f6sler","year":"2001","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.11.013_b0375","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000241881","article-title":"Evaluation of cerebrospinal fluid tau\/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease","volume":"62","author":"Smach","year":"2009","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0380","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neulet.2008.05.076","article-title":"CSF beta-amyloid 1\u201342 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele","volume":"440","author":"Smach","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0385","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","article-title":"Simultaneous measurement of beta-amyloid(1\u201342), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology","volume":"51","author":"Olsson","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0390","doi-asserted-by":"crossref","unstructured":"F. Ben Bouall\u00e8gue, D. Mariano-Goulart, P. Payoux, Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database, Alzheimers Res Ther 9(1) (2017) 32.","DOI":"10.1186\/s13195-017-0260-z"},{"issue":"11","key":"10.1016\/j.clinbiochem.2022.11.013_b0395","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jalz.2014.12.006","article-title":"CSF biomarkers for the differential diagnosis of Alzheimer's disease: a large-scale international multicenter study","volume":"11","author":"Ewers","year":"2015","journal-title":"Alzheimers Dement."},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.11.013_b0400","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.neurobiolaging.2006.12.010","article-title":"Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study","volume":"29","author":"Lewczuk","year":"2008","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.11.013_b0405","doi-asserted-by":"crossref","first-page":"e38639","DOI":"10.1371\/journal.pone.0038639","article-title":"Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study","volume":"7","author":"Palmqvist","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.11.013_b0410","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jalz.2012.09.016","article-title":"Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series","volume":"9","author":"Prestia","year":"2013","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0415","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study","volume":"5","author":"Hansson","year":"2006","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0420","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neurobiolaging.2007.06.009","article-title":"Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease","volume":"30","author":"Hansson","year":"2009","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.11.013_b0425","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ene.13881","article-title":"The combination of apolipoprotein E4, age and Alzheimer's disease assessment scale - cognitive subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment","volume":"26","author":"Ba","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0430","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.dadm.2018.07.002","article-title":"Derivation of cutoffs for the Elecsys(\u00ae) amyloid \u03b2 (1\u201342) assay in Alzheimer's disease","volume":"10","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0435","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2022.11.013_b0440","doi-asserted-by":"crossref","first-page":"e1917363","DOI":"10.1001\/jamanetworkopen.2019.17363","article-title":"Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment","volume":"2","author":"Garrett","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.11.013_b0445","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00406-013-0405-4","article-title":"Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease","volume":"263","author":"Guo","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0450","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.0b013e3181e8e8b8","article-title":"Comparing predictors of conversion and decline in mild cognitive impairment","volume":"75","author":"Landau","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.11.013_b0455","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/brain\/awaa165","article-title":"ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration","volume":"143","author":"Cousins","year":"2020","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0460","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-160143","article-title":"Analysis of cerebrospinal fluid and [11C]PIB PET biomarkers for Alzheimer's disease with updated protocols","volume":"52","author":"Wang","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0465","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0470","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ene.14658","article-title":"Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia","volume":"28","author":"\u00c1lvarez","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0475","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0197-4580(03)00086-1","article-title":"Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42\/Abeta40 ratio and total tau","volume":"25","author":"Lewczuk","year":"2004","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0480","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-140771","article-title":"Amyloid-\u03b2 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays","volume":"43","author":"Lewczuk","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0485","doi-asserted-by":"crossref","unstructured":"P. Lewczuk, A. Matzen, K. Blennow, L. Parnetti, J.L. Molinuevo, P. Eusebi, J. Kornhuber, J.C. Morris, A.M. Fagan, Cerebrospinal Fluid A\u03b242\/40 Corresponds Better than A\u03b242 to Amyloid PET in Alzheimer's Disease, J Alzheimers Dis 55(2) (2017) 813-822.","DOI":"10.3233\/JAD-160722"},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.11.013_b0490","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0197-4580(00)00164-0","article-title":"Relationship between apoE genotype and CSF beta-amyloid (1\u201342) and tau in patients with probable and definite Alzheimer's disease","volume":"21","author":"Tapiola","year":"2000","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.11.013_b0495","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000216841","article-title":"Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4\/epsilon4 genotype","volume":"27","author":"Blom","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0500","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40478-018-0624-z","article-title":"The relevance of cerebrospinal fluid \u03b1-synuclein levels to sporadic and familial Alzheimer's disease","volume":"6","author":"Twohig","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"10","key":"10.1016\/j.clinbiochem.2022.11.013_b0505","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00702-003-0017-7","article-title":"CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity","volume":"110","author":"Ganzer","year":"2003","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"16","key":"10.1016\/j.clinbiochem.2022.11.013_b0510","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease","volume":"289","author":"Sunderland","year":"2003","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0515","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3233\/JAD-180548","article-title":"Clinical experience with cerebrospinal fluid A\u03b242, total and phosphorylated Tau in the evaluation of 1,016 individuals for suspected dementia","volume":"65","author":"Tariciotti","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.11.013_b0520","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archneur.55.7.937","article-title":"High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype","volume":"55","author":"Galasko","year":"1998","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0525","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0530","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3233\/JAD-2009-1214","article-title":"Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease","volume":"18","author":"Lin","year":"2009","journal-title":"J. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.013_b0535","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/acn3.50873","article-title":"Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse","volume":"6","author":"Alcolea","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0540","doi-asserted-by":"crossref","first-page":"e12131","DOI":"10.1002\/dad2.12131","article-title":"Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: a comparison of Lumipulse and established immunoassays","volume":"13","author":"Keshavan","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.11.013_b0545","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00415-019-09418-6","article-title":"Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid A\u03b2(42) and T-Tau assays for Alzheimer's disease diagnosis","volume":"266","author":"Bayart","year":"2019","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0550","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","article-title":"Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease","volume":"11","author":"Leit\u00e3o","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0555","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/cclm-2021-0651","article-title":"Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid","volume":"60","author":"Gobom","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"issue":"11","key":"10.1016\/j.clinbiochem.2022.11.013_b0560","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer's disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0565","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.dadm.2018.08.006","article-title":"Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project","volume":"10","author":"Willemse","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"10.1016\/j.clinbiochem.2022.11.013_b0570","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","article-title":"Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging","volume":"14","author":"Schindler","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0575","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/alz.12406","article-title":"Detection of Alzheimer's disease amyloid beta 1\u201342, p-tau, and t-tau assays","volume":"18","author":"van Harten","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0580","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3233\/JAD-143099","article-title":"Diagnostic values of cerebrospinal fluid T-Tau and A\u03b2\u2084\u2082 using meso scale discovery assays for Alzheimer's disease","volume":"45","author":"Pan","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.11.013_b0585","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3233\/JAD-2012-121471","article-title":"A selected reaction monitoring (SRM)-based method for absolute quantification of A\u03b238, A\u03b240, and A\u03b242 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls","volume":"33","author":"Pannee","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.11.013_b0590","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-132489","article-title":"Qualification of a surrogate matrix-based absolute quantification method for amyloid-\u03b2\u2084\u2082 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry","volume":"41","author":"Korecka","year":"2014","journal-title":"J. Alzheimers Dis."},{"issue":"12","key":"10.1016\/j.clinbiochem.2022.11.013_b0595","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1373\/clinchem.2018.300947","article-title":"High-throughput mass spectrometry assay for quantifying \u03b2-Amyloid 40 and 42 in cerebrospinal fluid","volume":"65","author":"Weber","year":"2019","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.11.013_b0600","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13195-018-0362-2","article-title":"Addition of the A\u03b242\/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment","volume":"10","author":"Baldeiras","year":"2018","journal-title":"Alzheimers Res. Ther."},{"issue":"5","key":"10.1016\/j.clinbiochem.2022.11.013_b0605","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.neurobiolaging.2007.08.010","article-title":"Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment","volume":"30","author":"Brys","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0610","doi-asserted-by":"crossref","unstructured":"S.E. Schindler, J.G. Bollinger, V. Ovod, K.G. Mawuenyega, Y. Li, B.A. Gordon, D.M. Holtzman, J.C. Morris, T.L.S. Benzinger, C. Xiong, A.M. Fagan, R.J. Bateman, High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis, Neurology 93(17) (2019) e1647-e1659.","DOI":"10.1212\/WNL.0000000000008081"},{"issue":"7","key":"10.1016\/j.clinbiochem.2022.11.013_b0615","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","article-title":"Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-\u03b2 in cerebrospinal fluid","volume":"60","author":"Leinenbach","year":"2014","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.11.013_b0620","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","article-title":"Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results","volume":"64","author":"Tijms","year":"2018","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0625","doi-asserted-by":"crossref","unstructured":"Lewczuk, Piotr, Matzen, Anja, Blennow, Parnetti, Lucilla, Molinuevo, J. Luis, Eusebi, Cerebrospinal Fluid A beta(42\/40) Corresponds Better than A beta(42) to Amyloid PET in Alzheimer's Disease, Journal of Alzheimer\u2019s Disease 55 (2017) 813-822.","DOI":"10.3233\/JAD-160722"},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0630","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.604119","article-title":"Assessment of the concordance and diagnostic accuracy between elecsys and lumipulse fully automated platforms and innotest","volume":"13","author":"Dakterzada","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0635","article-title":"Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease","author":"Blennow","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0640","doi-asserted-by":"crossref","unstructured":"L. Vermunt, S.A.M. Sikkes, A. van den Hout, R. Handels, I. Bos, W.M. van der Flier, S. Kern, P.J. Ousset, P. Maruff, I. Skoog, F.R.J. Verhey, Y. Freund-Levi, M. Tsolaki, K. Wallin \u00c5, M. Olde Rikkert, H. Soininen, L. Spiru, H. Zetterberg, K. Blennow, P. Scheltens, G. Muniz-Terrera, P.J. Visser, Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype, Alzheimers Dement 15(7) (2019) 888-898.","DOI":"10.1016\/j.jalz.2019.04.001"},{"key":"10.1016\/j.clinbiochem.2022.11.013_b0645","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jsbmb.2016.03.012","article-title":"Age, APOE and sex: Triad of risk of Alzheimer's disease","volume":"160","author":"Riedel","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912022002636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912022002636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:10:41Z","timestamp":1762114241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912022002636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":129,"alternative-id":["S0009912022002636"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.11.013","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How far is the goal of applying \u03b2-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer\u2019s disease with standardization of measurements?","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}